Inhalon’s inhaled antibody therapy aims to address this need, the release said. Its RSV candidate is part of a more broad effort to develop therapies that deliver therapeutic antibodies directly to ...

The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

A team of researchers have made a new discovery in the field of hematology, providing an explanation for spontaneous and ...

Researchers have made a groundbreaking discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite treatment with ...

Lyn Iemma, aged 75 years at the time of writing, would not describe her life as dramatic. Born and raised in Perth, WA, Australia, this thriving but relaxed city is the place she has always called ...

Monoclonal antibodies, or mAbs, are important tools in medicine. These laboratory-made proteins are widely used in treatments ...

Vetigenics is seeing encouraging results of a completed study for an antibody aimed at treating oral melanoma in dogs, used ...

A team of researchers have made a new discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite treatment with full-dose ...

"Modifying the sugar parts of the antibody doesn't seem to affect its overall structure or how it behaves, which is important when developing antibodies as a treatment." Monoclonal antibodies are ...

Phase 3 trial results GSK5764227 (GSK) Antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload Treatment of relapsed ...

IgG1 antibodies make up at least some component of this response. Figure 3: Donor-specific antibody is formed during prolonged rejection-free survival after treatment with antibody against CD154.

CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating ...